Clinical utility and future perspectives of liquid biopsy in colorectal cancer
Liquid biopsy analyses of circulating tumor DNA are emerging as transformative tools for colorectal cancer management, enabling disease detection, monitoring, and treatment.
Liquid biopsy analyses of circulating tumor DNA are emerging as transformative tools for colorectal cancer management, enabling disease detection, monitoring, and treatment. Here, we critically assess its evidence-based utility in current clinical practice, seeking to align physicians’ and patients’ expectations.
Liquid biopsy offers a non‑invasive, real‑time approach to detect and monitor colorectal cancer, potentially guiding treatment decisions and improving patient outcomes in both metastatic and early‑stage settings.
Bizonyítékszint: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Kapcsolódó jelek
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics